Skip to search formSkip to main contentSkip to account menu

aclidinium

Known as: (3-Carbamoyl-3,3-diphenylpropyl)ethyldimethylammonium 
National Institutes of Health

Related topics

Related topics

3 relations
30 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza]aclidinium bromide

Narrower (1)

Tudorza

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
2019
2019
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
Background Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated… 
2017
2017
Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics.
Review
2016
Review
2016
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and health care expenditure worldwide… 
Review
2016
Review
2016
Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions
Asthma is a complex disease where many patients remain symptomatic despite guideline-directed therapy. This suggests an unmet… 
2014
2014
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
BACKGROUND: Treatment with either aclidinium (ACL) or formoterol (FOR) improves lung function and reduces symptoms in COPD… 
2014
2014
Cost-Effectiveness of Aclidinium Bromide Compared with Tiotropium Bromide from the Perspective of Copd Patient Populations
Objective: To assess the cost­effectiveness of aclidinium vs. tiotropium in GOLD II, III, & IV COPD patients from the perspective… 
2012
2012
Aclidinium
Aclidinium, an inhaled, long-acting antimuscarinic agent, has been developed as a twice-daily maintenance treatment for chronic… 
2012
2012
P189 Reduced COPD Exacerbations Associated with Aclidinium Bromide Versus Placebo: A Pooled Analysis of Phase III Data
Introduction and objective Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist indicated for the treatment… 
2012
2012
Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs
Introduction: Co-administration of a long-acting β-agonist with an anticholinergic is common clinical practice for the management… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)